International law firm Clifford Chance is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of the entire share capital of Diaverum from Bridgepoint Group. A transaction that will see M42 acquire a global renal care business.
M42 is a global tech-enabled healthcare leader operating at the forefront of medical development. Established after the coming together of G42 Healthcare and Mubadala Health, M42 combines unique medical and data-centric technologies with state-of-the-art facilities to deliver the highest level of precise, patient-centric, and preventative care.
Founded in 1991, Diaverum is currently the world’s third-largest provider of dialysis services, operating across 23 countries, with 440 clinics and over 13,000 employees. Diaverum is led by a highly experienced management team committed to improving medical outcomes for patients and driving innovation in tech-enabled care delivery.
The acquisition of Diaverum significantly expands M42’s global geographic footprint, enabling it to introduce relevant healthcare services and healthtech solutions in new markets while further enhancing its renal care offering in the GCC.
The transaction, which is subject to customary regulatory approvals, is expected to close later in 2023.
The Clifford Chance team advising M42 was led by UAE M&A partner Daud Khan (pictured) together with support from a core team comprising, senior associate Rizwan Butt, senior associate Kimberly Ng, associate Toyo Odetunde and trainee Leen Kayali. In addition, Partner Nicola Reader with senior associate Bola Coker lead on advising M42 on the acquisition financing and Partners Marc Besen and Dimitri Slobodenjuk, together with senior associate Hendrik Kuhn led on antitrust and foreign direct investment approval matters.